VERA Vera Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1831828 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-64.8%
TTM EPS YoY-47.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-113.5%
ROA-84.5%
ROIC (approx.)-87.8%
Asset turnover—
Leverage & solvency
Liabilities / assets28.5%
Debt / equity0.23x
Current ratio7.91x
Interest coverage-57.40x
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $215.26M | $126.17M | $78.22M | $68.99M | $22.48M |
| SG&A expense | $100.22M | $41.00M | $23.79M | $21.91M | $11.92M |
| Operating income | -$315.47M | -$167.17M | -$102.01M | -$90.90M | -$34.40M |
| Interest expense | $7.53M | $7.63M | $3.79M | $992,000 | $20,000 |
| Pretax income | -$299.61M | -$152.15M | -$95.99M | -$89.06M | -$32.61M |
| Income tax | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 |
| Net income | -$299.62M | -$152.15M | -$95.99M | -$89.06M | -$32.61M |
| EBITDA | -$315.00M | -$167.06M | -$101.99M | -$91.75M | -$34.23M |
| EPS (basic) | -4.66 | -2.75 | -2.25 | -3.35 | -2.43 |
| EPS (diluted) | -4.66 | -2.75 | -2.25 | -3.35 | -2.43 |
| Weighted avg. shares (diluted) | 64.23M | 55.33M | 42.71M | 26.57M | 13.44M |
| Balance sheet | |||||
| Cash & equivalents | $354.73M | $92.65M | $45.68M | $43.75M | $79.97M |
| Short-term investments | $359.86M | $548.21M | $115.03M | $71.19M | $0 |
| Receivables | $0 | — | — | — | — |
| Inventory | $0 | — | — | — | — |
| Current assets | $728.88M | $651.22M | $172.02M | $125.70M | $82.54M |
| PP&E, net | $1.37M | $960,000 | $92,000 | $51,000 | $0 |
| Intangibles | $0 | — | — | — | — |
| Total assets | $734.73M | $655.68M | $175.55M | $131.44M | $83.75M |
| Current liabilities | $53.45M | $25.37M | $22.30M | $25.60M | $7.69M |
| Long-term debt | $74.84M | $50.69M | $49.88M | $24.81M | $4.92M |
| Total debt | $74.84M | $50.69M | $49.88M | $24.81M | $4.92M |
| Total liabilities | $130.21M | $78.53M | $73.86M | $54.53M | $14.16M |
| Shareholders' equity | $604.52M | $577.15M | $101.69M | $76.91M | $69.59M |
| Net debt | -$279.89M | -$41.96M | $4.20M | -$18.94M | -$75.04M |
| Cash flow statement | |||||
| Operating cash flow | -$241.10M | -$134.68M | -$92.18M | -$67.60M | -$23.71M |
| Capital expenditure | $630,000 | $972,000 | $63,000 | $62,000 | $0 |
| Free cash flow | -$241.73M | -$135.65M | -$92.24M | -$67.66M | -$23.71M |
| Investing cash flow | $194.29M | -$425.03M | -$39.43M | -$70.55M | -$4.20M |
| Financing cash flow | $308.90M | $606.67M | $133.54M | $101.93M | $53.88M |
| Depreciation & amortization | $468,000 | $105,000 | $21,000 | -$846,000 | $176,000 |
| Stock-based compensation | $37.93M | $20.80M | $11.49M | $8.89M | $3.01M |
| Share buybacks | $0 | $13,000 | $0 | — | — |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.